Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Invested Capital (2016 - 2025)

Capricor Therapeutics has reported Invested Capital over the past 15 years, most recently at $305.8 million for Q4 2025.

  • Quarterly results put Invested Capital at $305.8 million for Q4 2025, up 110.22% from a year ago — trailing twelve months through Dec 2025 was $305.8 million (up 110.22% YoY), and the annual figure for FY2025 was $305.8 million, up 110.22%.
  • Invested Capital for Q4 2025 was $305.8 million at Capricor Therapeutics, up from $83.9 million in the prior quarter.
  • Over the last five years, Invested Capital for CAPR hit a ceiling of $305.8 million in Q4 2025 and a floor of -$1.8 million in Q3 2023.
  • Median Invested Capital over the past 5 years was $28.6 million (2021), compared with a mean of $55.3 million.
  • Biggest five-year swings in Invested Capital: crashed 111.53% in 2023 and later skyrocketed 3918.69% in 2024.
  • Capricor Therapeutics' Invested Capital stood at $32.0 million in 2021, then plummeted by 62.85% to $11.9 million in 2022, then skyrocketed by 90.32% to $22.6 million in 2023, then soared by 543.6% to $145.5 million in 2024, then skyrocketed by 110.22% to $305.8 million in 2025.
  • The last three reported values for Invested Capital were $305.8 million (Q4 2025), $83.9 million (Q3 2025), and $105.0 million (Q2 2025) per Business Quant data.